Metotrexato Doc Generici (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate production needed for purine and pyrimidine synthesis. This halts DNA, RNA and protein formation in rapidly dividing cells, providing immunosuppressive and anti‑cancer effects.

The dosage of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Regimens may range from low‑dose weekly injections for autoimmune disease to higher doses given in cycles for oncology, and must follow the prescriber’s instructions.

Methotrexate is teratogenic and contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Compared with biologic agents such as TNF‑α inhibitors, methotrexate is a small‑molecule drug that is less costly and can be administered by injection or orally. While biologics target specific cytokines, methotrexate has a broader mechanism affecting cell proliferation, which can be advantageous in certain patients but may carry a higher risk of systemic toxicity requiring regular monitoring.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and allow it to reach room temperature briefly before subcutaneous administration, following aseptic technique.

Metotrexato Doc Generici is supplied for subcutaneous injection. The prescribed dose is drawn into a sterile syringe and injected into the subcutaneous tissue, typically in the abdomen or thigh, using proper aseptic technique. Administration is usually performed once weekly for autoimmune conditions, or as part of a chemotherapy cycle for oncologic indications, as directed by the healthcare provider.

The most critical risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to pancytopenia, and renal impairment. These adverse events can be life‑threatening and require regular laboratory monitoring, prompt recognition of symptoms, and immediate medical attention if they occur.

Patients with known hypersensitivity to methotrexate or any component of the formulation, those with severe renal or hepatic impairment, active infections, or pregnant and breastfeeding women should not receive this medication. Additionally, individuals receiving live vaccines or with uncontrolled immune disorders should avoid its use unless specifically directed by a specialist.